Cargando...
The emerging role of CDK4/6i in HER2-positive breast cancer
Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. In the era of effective HER2-directed therapies, median survival rates for pat...
Guardado en:
| Publicado en: | Ther Adv Med Oncol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6887797/ https://ncbi.nlm.nih.gov/pubmed/31832106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919887665 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|